Erasca revamps pipeline, laying off staff as it licenses cancer drugs from China and nabs $160M

17 May 2024
endpts.com
Erasca is looking for a refresh as it drops several early-stage cancer assets, picks up new ones from China and raises cash to help push its lead candidate to the finish line.
The San Diego biotech said late Thursday that it is deprioritizing its ERK 1/2 inhibitorERK 1/2 inhibitor ERAS-007 and pan-KRAS candidate ERAS-4. As for the EFGR inhibitor ERAS-801, patient enrolment will be paused according to Mizuho analysts, citing a conversation with Erasca execs, but Erasca said the drug will be further explored in investigator-led trials.
Erasca revamps pipeline, laying off staff as it licenses cancer drugs from China and nabs $160M
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.